NEW YORK (GenomeWeb News) — Personalized medicine company Serametrix announced today a partnership with the Ludwig Institute for Cancer Research to develop serum-based diagnostics to predict and monitor treatment response in cancer patients.
As part of the agreement, LICR has licensed to Serametrix tumor antigen patents surrounding the use of the antigen NY-ESO-1 as a predictor of drug response.
In exchange, LICR will take an undisclosed equity stake in Serametrix. In addition, Lloyd Old, director of LICR's New York branch, has been appointed chairman of Serametrix's scientific advisory board.
Additional terms of the licensing deal were not disclosed.
Serametrix also said that it will add to its current array-based services by launching a serum-profiling service dedicated solely to NY-ESO-1 antibody detection. Serametrix said that it believes the test will have immediate application in the clinical development of cancer therapies.